Clinical-stage biotech developing long-acting antibody drugs for psoriasis and other skin/inflammatory diseases.
Clinical-stage biotech developing long-acting antibody drugs for psoriasis and other skin/inflammatory diseases.
Moat: none (IP / patents). Pre-commercial; strategy is to engineer less-frequent-dosing antibodies against validated psoriasis targets.
Headquarters: Waltham, Massachusetts, United States · Founded: 2023 · Employees: 68
Size Oruka Therapeutics (ORKA) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $6.49B, the 1001st largest of 3,085 United States companies the cockpit tracks. Shares closed at $95.74 on 18 Nov 2026.
Performance Over six months the shares gained 57.8%, against -4.6% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 20 in its peer set.
Capital Return on invested capital runs 57.9 points below its cost of capital (6.6% WACC).
Short interest Short interest is 9.8% of the free float (30 Oct 2026).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | -$163,000 | -$83,000 | -$27,000 | -$111,000 | -$114,000 |
| EBITDA | -$183M | -$122M | -$88.1M | -$7.18M | -$9.73M |
| Net income | -$153M | -$105M | -$83.7M | -$5.34M | -$9.93M |
| Free cash flow | -$124M | -$88.4M | -$58.0M | -$5.01M | -$10.9M |
| Capital expenditure | $219,000 | $209,000 | $189,000 | $0 | $2,000 |
| Total debt | $2.93M | $1.93M | $968,000 | $280,000 | $383,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Oruka Therapeutics ORKA | $6.49B | +58% | n/a | n/a | n/a | n/a |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 6.9× | 3.7% |
| Novartis NOVN.SW | $285B | +11% | -4% | 30% | 6.2× | 1.6% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 8.7× | -0.1% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 15.6× | 6.5% |
| Bristol Myers Squibb BMY | $122B | +3% | +4% | 33% | 3.1× | -13.1% |
| Alumis ALMS | $569M | -80% | -67% | -5,375% | 23.9× | n/a |
| Takeda Pharmaceutical 4502.T | $69.8B | +30% | +6% | 18% | 3.2× | 3.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ORKA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +21.1% | -2.1% | 2nd highest of 21 |
| 6-month return | +57.8% | -4.6% | highest of 20 |
| Distance from 52-week high | -17.1% | -25.4% | 9th highest of 21 |
| ROIC minus cost of capital | -57.9 pp | +2.2 pp | lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 5.9× | n/a | n/a |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 3.5× | -11.9% | +4.2% |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 1.9× | -6.2% | +18.4% |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 4.3× | n/a | n/a |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 4.1× | 25.0% | +10.7% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 1.1× | -3.9% | +5.3% |
| RemeGen 688331.SS | China | $6.28B | -24% | +272% | 61% | 4.4× | 1.1% | +303.3% |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | 9.6× | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | 12.9× | n/a | n/a |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 4.5× | 6.2% | +13.9% |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 8.6× | n/a | n/a |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 26.3× | 57.7% | +7.5% |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $7.10B | +17% | +24% | 17% | 5.8× | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | 44.3× | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | 64.3× | n/a | n/a |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 7.3× | 8.0% | +10.0% |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 2.1× | -6.8% | +10.8% |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 7.1× | 20.2% | +13.3% |
| Corcept Therapeutics CORT | United States | $7.42B | +15% | +30% | 12% | 7.3× | 23.9% | +16.6% |